FDA Oncologic Drugs Advisory Committee Recommends REVLIMID for Full Approval
15th Sep 2005, 14:17 GMT
By a 10-5 Vote, ODAC Recommends REVLIMID as Oral Targeted Therapy for Low to Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality
Latest news from Radiology News from myHealthcareNews.com:
- Genzyme increasing R&D presence in San Antonio area
- Eisai Breaks Ground for New Oncology Facility in Research Triangle Park
- Ashok Gupta, MD Joins the Physician Team at Desert Radiologists
- AMICAS Offers Free PACS Webinar for RSNA Attendees
- Enrollment Completed Utilizing Cytori's Adipose-Derived Stem Cell Technology for Treatment of Breast Cancer Complications
- Groundbreaking for Cancer Center on Premier Healh Campus - Middletown
- BSD Medical Sends Message of Hope at Largest Conference of US Radiation Oncologists
- Volcano to Offer 7.5M Shares
- Nautilus Biotech and Creabilis Therapeutics Achieve Technical Milestone in Collaboration to Improve HMGB1 Box A for the Treatment of Rage- and HMGB1-Related Pathologies.
- Adherex Reports Q3 2006 Financial Results